Insight

Jun 1, 2025, 16:23

Key Insights by Talha Badar from ASCO25

The American Society of Clinical Oncology (ASCO) 2025 annual meeting once again showcased groundbreaking research across the spectrum of hematologic malignancies. Among those providing expert updates from the conference, Dr. Talha Badar shared a series of insightful posts on his Twitter page, highlighting notable studies in leukemia, myelodysplastic syndromes (MDS), myelofibrosis, and chronic myeloid leukemia (CML).

Some of the ASCO 2025 Highlights Shared by Talha Badar:

Combination Therapy in Ph+ ALL Shows Deep Molecular Responses

Ph+ ALL phase 1 study presented by Dr Marlise R. Luskin, Asciminib+Dasatinib+Prednisone followed by blinatumomab is safe and effective in achieving deep molecular remission.

Talha Badar

Ponatinib Benefits Patients with Delayed MRD Negativity in PhALLCON

Dr. Ibrahim Aldoss presented post hoc analysis of PhALLCON study. Pt who didn’t achieve molecular MRD end of induction and continued on therapy beyond C3. High % of pts achieved MMR in ponatinib arm without added toxicity.

Talha Badar

BEXMAB Study Highlights Novel CLEVER-1 Target in High-Risk MDS

MDS, mdssm, BEXMAB p1/2 study in HR-MDS presented by Dr. Naval Daver. bexmarlimab (CLEVER-1 macrophage immune check point inhibitor) in combination with AZA ORR 72% in frontline and 63% in RR (post HMA) mOS in RR MDS 13.4 Overall > 40% pt had TP53m.

Talha Badar

Metronomic Decitabine+Venetoclax Offers Hope in TP53-Mutant MDS/AML

Dr. Mendel Goldfinger present metronomic dosing of decitabine +ven for TP53m MDS/AML. mOS 11.3 mo, better in SH TP53. Better tolerance.

Talha Badar

Imetelstat + Ruxolitinib Shows Activity in Myelofibrosis

IMproveMF trial presented by Dr. John Mascarenhas, Imetelstat combined with stable dose of Jakafi. No significant inc in cytopenia. Symptom and SVR. Decrease in mutation burden of driver mutations.

Talha Badar

CML TKI Selection Should Be Individualized

CML “best choice of frontline TKI for CML” educational session, presented by Dr. Timothy Hughes.

1. No TKI is best for every pts, choice should be individualized based on pt profile.

2. Asciminib may be a better choice for younger pt looking for TFR, except for ASXL1, e13a3 or e14a3 ABL variants.

3. Imatinib may be better suited for elderly.

4. Dasatinib has comparable effectiveness at lower doses, can be used in older pts.

Dr. Talha Badar’s coverage from ASCO 2025 underscores the dynamic evolution of therapeutic strategies in hematologic malignancies. Whether through innovative combination regimens, precision medicine based on molecular risk, or individualized treatment selection, the findings shared reflect an ongoing commitment to improving patient outcomes. These highlights capture just a fraction of the advancements unveiled at ASCO, yet they offer powerful insight into where the field is heading in the near future.

If you found these updates valuable, be sure to follow OncoDaily for more real-time insights, expert commentary, and stories that matter in the world of oncology. Stay informed—because progress in cancer care is a journey we’re all part of.